Market news
Smart Beta ETF report for XHS
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.
Motley Fool Press Release.
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Smart Beta ETF report for XHB
State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers.
One fund targets pharma exclusively and surged 63% in a year, while the other diversifies across healthcare with lower volatility.
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.
Detailed price information for Invesco Limited (IVZ-N) from The Globe and Mail including charting and trades.
Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.
This is the newest page. Registered accounts read further back.